Catalyst Pharmaceuticals Inc. (CPRX), which achieved over 23% revenue growth in 2024, expects continued growth in 2025, reflecting confidence in its ongoing momentum.
The company's marketed drugs include Firdapse, which is approved for the treatment of adult patients with Lambert-Eaton myasthenic syndrome, the anti-epileptic drug Fycompa, and the Duchenne muscular dystrophy drug Agamree.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com